by 
The bispecific antibodies market has gained significant traction in recent years owing to the advantages offered by these antibodies over conventional monoclonal antibodies. Bispecific antibodies allow targeting of two or more antigens or epitopes simultaneously, making them an attractive therapeutic approach for various cancers and other diseases. These antibodies have two binding regions – one for tumor-associated antigens and one for T-cell activation – enabling them to bring T cells and tumor cells together to drive targeted killing of cancerous cells. The bispecific antibodies therapies are increasingly being explored for their potential to treat various hematological and solid tumors with high efficacy and improved safety.
The Global bispecific antibodies market is estimated to be valued at US$ 41.08 Mn in 2024 and is expected to exhibit a CAGR of 29% over the forecast period 2023 to 2030.
Key Takeaways
Key players operating in the bispecific antibodies market are Amgen, Inc., Bayer AG, Dow Pharmaceutical Solutions, ImmunGene, Inc., Immunocore Limited, Merck & Co., Inc., Novartis AG, Pfizer, Inc., and F. Hoffmann-La Roche AG.
The key opportunities in the market include the large number of bispecific antibodies in clinical trials targeting various cancer indications. Additionally, the shift from monoclonal to novel biologics like bispecific antibodies for cancer treatment also presents significant prospects.
Globally, the market is witnessing strong growth in the North American and European regions due to rising cancer prevalence and growing adoption of biologics. However, the Asia Pacific region is also expected to showcase high growth over the forecast period supported by increasing healthcare spending and expanding patient pool in countries like China and India.
Market drivers
Rising cancer incidence rates globally have increased the demand for advanced treatment options with improved efficacy. As per Globocan 2020, the number of new cancer cases and cancer-related deaths worldwide were estimated to be 19.3 million and 10.0 million respectively in 2020. Furthermore, the limitations of conventional monoclonal antibodies and chemotherapy in targeting solid tumors have fueled investments in the research and development of bispecific antibodies.
PEST Analysis
Political: Regulations regarding drug development and approval processes can impact the growth and progress of players in this market. Stringent rules for clinical trials and product approvals pose challenges.
Economic: Continuous funding for research and development from private and public sources are fueling advancements in bispecific antibody technology. High treatment costs of cancer and other diseases increase the demand.
Social: Rising incidence of cancer and other chronic diseases drives the need for more effective treatment options. Growing awareness about personalized medicines influences research.
Technological: Developments in antibody engineering, molecular design and protein engineering have enabled the design of novel bispecific antibodies. Increased investments are strengthening infrastructure for research.
Geographical Concentration
North America region accounts for the largest share of the bispecific antibodies market in terms of value currently. This is attributed to established healthcare infrastructure, high adoption of advanced therapeutics, and major market players domiciled in the region.
Fastest Growing Region
Asia Pacific region is poised to witness the fastest growth over the forecast period owing to increasing healthcare spending, large patient pool, rising disposable incomes, and growing focus of international players on establishing manufacturing and research facilities in countries like China and India.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
